


## **Domenico LAZZARO, M.D pathologist, joins HISTALIM which enforces thanks to his expertise its positioning on the tumor immuno-profiling.**

**HISTALIM is glad to announce the appointment of Dr Domenico LAZZARO in its laboratory of Montpellier. Dr. Lazzaro is a specialist in anatomical pathology and cytology and holds a PhD in experimental medicine and molecular pathology.**

Montpellier, 30th August 2017

---

**D**r LAZZARO's experiences perfectly illustrate the unique medical expertise, as well as the scientific excellence that drives his professional career. Domenico lead the "In Vivo Drug Efficacy" group of Merck Research Laboratories for 16 years where he developed animal models to test cancer vaccine efficacy for human therapies as well as anti-tumoral small molecules and therapeutic antibodies. He also developed IHC based companion diagnostic tests for cancer targeted therapies. Domenico was Professor of Cancer Ultrastructural Pathology at the University of Tor Vergata (Italy), contract professor of immunopathology at the Department of Public Health University of Foro Italico in Roma (Italy) and also established his experience at the European Molecular Biology Laboratory in Heidelberg (Germany).



Domenico LAZZARO, M.D pathologist.

This new position represents an important milestone for HISTALIM's development and enforces its market leader position in the framework of clinical trial histopathology, particularly in Immuno-oncology.

### **Press contact**

Jean-Philippe COTON - HISTALIM CEO +33 619 646 737 [contact@histalim.com](mailto:contact@histalim.com)

---

## **About HISTALIM**

HISTALIM is a European leading company in the field of histopathology and tissue based assays. The company collaborates with pharmaceutical groups and biotech at each stage of their development and experience an accelerated growth thanks to its highly value-added services in the development of immuno-oncology and biotherapies.

